Spotlight - Information about FUJIFILM Europe

Spotlight 55: Continuously promoting R&D of anti-cancer drugs

Cancer R&D progressFujifilm is dedicated to R&D for innovative pharmaceutical products by combining the technologies and know-how accumulated in the photographic film business including chemical synthesis capacity, design ability, analysis technology, nanotechnology, and production technology, with the technological expertise of its pharmaceutical affiliates such as Toyama Chemical. Oncology, a field with numerous unmet medical needs, has been defined as one of the focal areas. Recently progress in a Phase I clinical trial of anti-cancer agent FF-10501 in the United States in patients with relapsed or refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) was announced. The emerging results have revealed that to date FF-10501 was well tolerated in those patients. More about anti-cancer agent FF-10501: